A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Astellas

Status and phase

Completed

Phase 2

Conditions

Overactive Bladder

Treatments

Drug: YM178

Study type

Interventional

Funder types

Industry

Identifiers

NCT00337090

178-CL-044

Details and patient eligibility

About

The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.

Enrollment

1,108 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months

Exclusion criteria

Pregnant and breastfeeding women
Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)